辉瑞表示,其在比利时Puurs的生产基地是该公司最大的无菌注射基地之一,对于在英国的分销至关重要针对美国市场。 BioNTech生产了用于临床试验的候选疫苗剂量,并可以通过其在德国Mainz和Idar-Oberstein的现有mRNA生产基地生产商业供应的mRNA。 BioNTech表示,到2021年,一旦德国的第三个生产基地开始运营,它将能够提高其生产能力。
. Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech is able to produce mRNA for commercial supply after having already produced the vaccine candidate doses for the clinical trials. BioNTech will also increase its manufacturing capacity...
There are additional factories in Mainz and Idar-Oberstein, Germany that supply at least part of the vaccine. A third German site is being built. The Puurs facility will be used primarily for European supply, but will act as a back-up to the Kalamazoo site for the U.S. m...
Pfizer and BioNTech announced the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use Authoriz...
(Massachusetts, Michigan and Missouri) and Puurs, Belgium have been identified as manufacturing centers for COVID-19 vaccine production, with more sites to be selected. Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNT...